FDA may loosen sales of Merck's Mevacor |
|
|
|
Published
:
Tue, 23 Oct 2007 20:26
|
WASHINGTON (AP) - Drug maker Merck will attempt to convince government health advisers in December that its cholesterol-lowering pill Mevacor is safe enough to be sold without a prescription.The Food and Drug Administration will ask a panel of outside experts on Dec. 13 to weigh new data from Merck that support use of the drug as an over-the-counter treatment. FDA is not required to follow the panel's advice, though it usually does.Specifically, Whitehouse Station, New Jersey-based Merck is asking FDA to approve Mevacor as a once-a-day pill to lower cholesterol and prevent heart attack. FDA rejected a similar request from the company in 2005.Total sales of Mevacor, which competes against generic versions, totaled $20 million last year.Shares of Merck & Co. Inc. rose $1.31, or 2.4 percent, to $55.96 in afternoon trading.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2251.69 |
-12.87 (
-0.56 %)
|
| SYMBOL (
2010-07-29 ) |
| LAST |
CHANGE
|
|
KAZAKHMYS
(
11:37am )
|
|
1220.00 |
+23.00 (
1.91 %)
|
|
LONMIN
(
11:35am )
|
|
1580.00 |
+21.00 (
1.35 %)
|
|
SHIRE
(
11:35am )
|
|
1490.00 |
+21.00 (
1.43 %)
|
| SYMBOL (
2010-07-29 )
|
| LAST |
CHANGE
|
|
DUPONT
(
4:00pm ) |
|
40.51 |
+0.24 (
0.59 %)
|
| SYMBOL (
2010-07-29 )
|
| LAST |
CHANGE
|
|
|
Print this Story
ImClone, Bristol-Myers, Merck KGaA to jointly develop, market Erbitux in Japan 